Despite the relatively small number of patients, our AML cohort appears representative of the general AML population, since the overall frequency of IDH mutations among AML patients in this study was 17.9% (with an IDH1 frequency of 7.2% and an IDH2 frequency of 10.7%), which is similar to those reported by others [15, 47]. The gene discussed is IDH1; the disease is acute myeloid leukemia.